Assessment of oleoylethanolamide supplementattion in the prevention and treatment of obesity

Assessment of oleoylethanolamide supplementattion on the peroxisome proliferator-activated receptor-a (PPAR-a) gene expression, some inflammatory biomarkers, total antioxidant capacity, lipid profiles, fasting blood glucose, food intake and the abundence of Akkermansia muciniphila bacteria in stool of obese people: A double-blind randomized placebo-controlled clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201607132017N30

Enrollment

Registered

2016-10-03

Start date

2016-09-22

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obesity. Obesity due to excess calories

Interventions

Intervention 1: intervention group: daily 2 capsules including 125 mg oleoylethanolamide for eight weeks. Intervention 2: control group: daily 2 capsule including 125 mg starch for eight weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: healthy obese subjects in both genders (males and females) Ages between 18 to 59 years body mass index 30-40 kg/m2

Exclusion criteria

Exclusion criteria: having kidney problems, liver failure, heart failure, rheumatic diseases and gastrointestinal diseases smoking Breastfeeding and pregnancy and menopause Taking probiotic and prebiotic supplements, vitamin, minerals, omega-3 and weight-reducing drugs and antibiotics during past one month

Design outcomes

Primary

Measure	Time frame
Gene expression of PPAR-a. Timepoint: before and after supplementation. Method of measurement: Real time-PCR.;Inflammatory biomarkers (IL-6? TNF-a ? hs-CRP). Timepoint: before and after supplemenation. Method of measurement: IL-6 and TNF-a using ELISA, hs-CRP using spectrometry method.;The abundance of Akkermansia muciniphila bacteria in stool samples. Timepoint: before and after supplemenation. Method of measurement: colony count.;Total antioxidant capacity. Timepoint: before and after supplemenation. Method of measurement: using ELISA method.;Lipid profiles and fasting blood glucose. Timepoint: before and after supplementation. Method of measurement: Using ELISA method.;Dietary intake. Timepoint: before and after supplemenation. Method of measurement: Three days food record questionnaire.	—

Measure

Time frame

Gene expression of PPAR-a. Timepoint: before and after supplementation. Method of measurement: Real time-PCR.;Inflammatory biomarkers (IL-6? TNF-a ? hs-CRP). Timepoint: before and after supplemenation. Method of measurement: IL-6 and TNF-a using ELISA, hs-CRP using spectrometry method.;The abundance of Akkermansia muciniphila bacteria in stool samples. Timepoint: before and after supplemenation. Method of measurement: colony count.;Total antioxidant capacity. Timepoint: before and after supplemenation. Method of measurement: using ELISA method.;Lipid profiles and fasting blood glucose. Timepoint: before and after supplementation. Method of measurement: Using ELISA method.;Dietary intake. Timepoint: before and after supplemenation. Method of measurement: Three days food record questionnaire.

—

Secondary

Measure	Time frame
Anthropometric measurements. Timepoint: at baseline and at the end of intervention. Method of measurement: Using a stadiometertape and tape in accordance with the standards.;Appetite status. Timepoint: at baseline and at the end of study. Method of measurement: Visual Analouge Scale questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLaleh Payahoo

Faculty of Nutrition, Tabriz University of Medical Science

Llllpayahoo44@gmail.com+98 41 3335 7580

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 6, 2026